Update on the Management of Aspirin-Exacerbated Respiratory Disease.
10.4168/aair.2016.8.4.298
- Author:
Kathleen M BUCHHEIT
1
;
Tanya M LAIDLAW
Author Information
1. Department of Medicine, Harvard Medical School, Boston, MA, USA. kbuchheit@partners.org
- Publication Type:Review
- Keywords:
Aspirin-exacerbated respiratory disease;
Samter's triad;
nasal polyps;
aspirin desensitization
- MeSH:
Aspirin;
Asthma;
Cyclooxygenase 1;
Eosinophils;
Humans;
Nasal Polyps
- From:Allergy, Asthma & Immunology Research
2016;8(4):298-304
- CountryRepublic of Korea
- Language:English
-
Abstract:
Aspirin-exacerbated respiratory disease (AERD) is an adult-onset upper and lower airway disease consisting of eosinophilic nasal polyps, asthma, and respiratory reactions to cyclooxygenase 1 (COX-1) inhibitors. Management includes guideline-based treatment of asthma and sinus disease, avoidance of COX-1 inhibitors, and for some patients aspirin desensitization followed by high-dose aspirin therapy. Despite this, many patients have inadequately controlled symptoms and require multiple sinus surgeries. In this review, we discuss the current standard approaches to the management of AERD, and we introduce several therapeutics under development that may hold promise for the treatment of AERD.
